|
Pharmacogenomics of irinotecan
Keck School of Medicine, USC/Norris Cancer Center, Los Angeles, CA
Although the clinical importance of genetic testing has not been uniformly established for all tumor types, treatment-related genetic variables will certainly become part of survival planning as the field of pharmacogenetics matures. Many practical issues await resolution before genetic screening for clinically relevant polymorphisms becomes a reality. Until then, clinical considerations such as volume status, renal function, and preexisting bowel dysfunction may suggest the need to modify the dosage or mode of administration of irinotecan for patients with metastatic colorectal cancer.
| Commun Oncol 2007;4(suppl 2):21–24 | full text |  124 kb |